GSK's antibody-drug conjugate Blenrep for multiple myeloma faces scrutiny over its safety and efficacy from the FDA's Oncologic Drugs Advisory Committee. Originally approved in 2020, the drug was withdrawn from the U.S. market after a failed confirmatory study. New data from late-stage trials suggest efficacy in subsets of patients, but FDA reviewers raised concerns about high rates of severe ocular toxicities, including vision loss, and unclear optimal dosing. These issues pose risks to patient quality of life and have complicated the risk-benefit assessment for the drug’s reapproval. The advisory committee is set to discuss these concerns in an upcoming meeting.